Cargando…

The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration

[Image: see text] Psoralen is a furanocoumarin compound found in many herb medicines and is claimed to contribute to the hepatotoxicity caused by lots of traditional Chinese medicine. So far, there has been no research on the differences in pharmacokinetics of single and repeated dosing of psoralen....

Descripción completa

Detalles Bibliográficos
Autores principales: Yang, Li, Yu, Ying-li, Cheng, Li-yuan, Zhang, Pan-yang, Zhang, Yue, Zhou, Kun
Formato: Online Artículo Texto
Lenguaje:English
Publicado: American Chemical Society 2020
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144168/
https://www.ncbi.nlm.nih.gov/pubmed/32280872
http://dx.doi.org/10.1021/acsomega.9b04153
_version_ 1783519784645689344
author Yang, Li
Yu, Ying-li
Cheng, Li-yuan
Zhang, Pan-yang
Zhang, Yue
Zhou, Kun
author_facet Yang, Li
Yu, Ying-li
Cheng, Li-yuan
Zhang, Pan-yang
Zhang, Yue
Zhou, Kun
author_sort Yang, Li
collection PubMed
description [Image: see text] Psoralen is a furanocoumarin compound found in many herb medicines and is claimed to contribute to the hepatotoxicity caused by lots of traditional Chinese medicine. So far, there has been no research on the differences in pharmacokinetics of single and repeated dosing of psoralen. Moreover, the research on the cumulative toxicity of low concentration and long-term administration on cells has not been reported. Therefore, this study investigated the pharmacokinetic differences and the accumulated cytotoxicity of psoralen from repeated administration. The study found that after single or repeated administration of psoralen for 3 months at various dosages (14, 28, and 56 mg/kg), the pharmacokinetic parameters of female rats between single dose and repeated dose administration are totally different. Compared with a single administration, multiple administrations increased psoralen’s in vivo exposure, prolonged the peak time, prolonged the half-life of the drug, reduced the drug clearance rate, and prolonged the drug’s stay in the body. HepG2 cells were exposed to low doses (5, 10, 20, or 40 μM) of psoralen for 1, 2, 3, or 4 days. A 20 and 40 μM dose of psoralen did not induced cell death in the 1st day but significantly decreased the cell viability at the 3rd and 4th day of repeated administration, respectively. In addition, multiple administrations of psoralen decreased cell viability due to G2 arrest.
format Online
Article
Text
id pubmed-7144168
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher American Chemical Society
record_format MEDLINE/PubMed
spelling pubmed-71441682020-04-10 The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration Yang, Li Yu, Ying-li Cheng, Li-yuan Zhang, Pan-yang Zhang, Yue Zhou, Kun ACS Omega [Image: see text] Psoralen is a furanocoumarin compound found in many herb medicines and is claimed to contribute to the hepatotoxicity caused by lots of traditional Chinese medicine. So far, there has been no research on the differences in pharmacokinetics of single and repeated dosing of psoralen. Moreover, the research on the cumulative toxicity of low concentration and long-term administration on cells has not been reported. Therefore, this study investigated the pharmacokinetic differences and the accumulated cytotoxicity of psoralen from repeated administration. The study found that after single or repeated administration of psoralen for 3 months at various dosages (14, 28, and 56 mg/kg), the pharmacokinetic parameters of female rats between single dose and repeated dose administration are totally different. Compared with a single administration, multiple administrations increased psoralen’s in vivo exposure, prolonged the peak time, prolonged the half-life of the drug, reduced the drug clearance rate, and prolonged the drug’s stay in the body. HepG2 cells were exposed to low doses (5, 10, 20, or 40 μM) of psoralen for 1, 2, 3, or 4 days. A 20 and 40 μM dose of psoralen did not induced cell death in the 1st day but significantly decreased the cell viability at the 3rd and 4th day of repeated administration, respectively. In addition, multiple administrations of psoralen decreased cell viability due to G2 arrest. American Chemical Society 2020-03-24 /pmc/articles/PMC7144168/ /pubmed/32280872 http://dx.doi.org/10.1021/acsomega.9b04153 Text en Copyright © 2020 American Chemical Society This is an open access article published under an ACS AuthorChoice License (http://pubs.acs.org/page/policy/authorchoice_termsofuse.html) , which permits copying and redistribution of the article or any adaptations for non-commercial purposes.
spellingShingle Yang, Li
Yu, Ying-li
Cheng, Li-yuan
Zhang, Pan-yang
Zhang, Yue
Zhou, Kun
The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title_full The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title_fullStr The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title_full_unstemmed The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title_short The Accumulation of Psoralen Contributes to Its Hepatotoxicity Revealed by Pharmacokinetic and Toxicokinetic Study after Repeated Administration
title_sort accumulation of psoralen contributes to its hepatotoxicity revealed by pharmacokinetic and toxicokinetic study after repeated administration
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7144168/
https://www.ncbi.nlm.nih.gov/pubmed/32280872
http://dx.doi.org/10.1021/acsomega.9b04153
work_keys_str_mv AT yangli theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT yuyingli theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT chengliyuan theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhangpanyang theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhangyue theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhoukun theaccumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT yangli accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT yuyingli accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT chengliyuan accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhangpanyang accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhangyue accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration
AT zhoukun accumulationofpsoralencontributestoitshepatotoxicityrevealedbypharmacokineticandtoxicokineticstudyafterrepeatedadministration